SIRT6 and metabolic dysfunction-associated steatotic liver disease: Mechanistically, our data suggest that hepatocyte SIRT6 likely inhibits the development of NAFLD by suppressing de novo lipogenesis, lipid droplet formation, the p53 pathway, and inflammation.